drugset / Trial / NCT05965583

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the Blood

NCT05965583 ↗

Phase 1 Completed 14 enrolled Boehringer Ingelheim
NaCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect on the exposure of BI 1815368 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as oral single dose (Reference, R).

Timeline

Start
2023-08-02
Primary completion
2023-10-24
Completion
2023-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1815368 Unknown — Oral
Subject Itraconazole Small molecule 200 mg Oral

Indications

No indication recorded.